1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY.SW
Bristol-Myers Squibb CompanyCH flagSwiss Exchange
42.54
USD
-1.96
- -
70.70BMarket Cap
Bristol-Myers Squibb Company
BMY.SW
(Swiss Exchange)

Recent

price

42.54

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
18.83
21.54
21.67
21.75
23.83
23.69
23.81
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-3.99
3.25
2.97
3.88
-4.41
3.47
3.57
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6.22
7.53
6.13
6.7
7.49
6.96
6.53
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.8
2.04
2.18
2.29
2.4
2.48
2.49
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9.55
11.2
12.11
14.04
7.5
8.45
9.12
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-15.99
-12.67
-12.39
-9.26
-14.29
-11.11
-9.89
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2,258
2,153
2,130
2,069
2,027
2,034
2,036
Basic Weighted Avg Shares
19,484
21,244
17,621
16,385
15,879
16,560
19,427
20,776
22,561
26,145
42,518
46,385
46,159
45,006
48,300
48,195
48,483
Sales/Revenue/Turnover
30.54
31.24
22.31
17.89
10.79
10.45
23.36
16.59
22.79
16.5
5.15
18.4
19.72
18.21
12.19
28.48
28.03
Operating Margin (%)
607
628
681
763
467
376
382
789
637
1,746
10,380
10,686
10,276
9,760
9,600
4,011
3,593
Depreciation Expense
3,102
3,709
1,960
2,563
2,004
1,565
4,457
1,007
4,920
3,439
-9,015
6,994
6,327
8,025
-8,948
7,054
7,275
Net Income, GAAP
25.66
24.65
- -
10.76
14.78
21.47
23.8
81
17.11
30.45
- -
13.39
17.74
4.74
- -
24.36
24.22
Effective Tax Rate (%)
15.92
17.46
11.12
15.64
12.62
9.45
22.94
4.85
21.81
13.15
-21.2
15.08
13.71
17.83
-18.53
14.64
15.01
Profit Margin (%)
6,534
7,538
1,242
6,476
6,147
2,398
4,863
5,291
7,062
11,050
11,112
11,394
5,383
9,508
6,006
5,973
8,050
Working Capital
5,328
5,376
6,568
7,981
7,242
6,550
5,716
6,975
5,646
44,059
49,169
40,479
36,317
38,183
48,973
44,676
43,922
LT Debt
15,638
15,867
13,638
15,236
14,983
14,424
16,347
11,847
14,127
51,698
37,882
36,006
31,118
29,485
16,388
18,506
20,102
Total Equity
20.83
23.52
- -
11.69
6.26
6.1
15.51
3.06
20.59
4.92
- -
8.64
9.75
10.86
- -
15.61
15.17
Return on Invested Capital (%)
4.83
5.97
- -
6.65
5.23
4.14
11.44
2.69
12.43
6.24
- -
11.36
10.74
13.3
- -
12.97
13.03
Return on Capital (%)
9.87
11.39
5.92
7.75
6.08
4.85
13.6
3.09
14.98
9.96
-32
30.62
25.36
29.26
-40.43
43.55
41.6
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
4,723
2,463
2,506
LT Borrowings
44,469
42,850
42,152
LT Finance Leases
1,849
1,826
1,770
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,036
2,036
2,042
Market Capitalization
- -
87,280
86,622

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
35,630
29,390
27,208
Cash, Cash Equivalents & STI
16,502
10,673
10,486
Accounts Receivable, Net
9,624
9,592
7,947
Inventories
2,758
2,690
2,756
Total Current Liabilities
28,136
23,417
19,158
Payables & Accruals
7,084
6,321
6,936
ST Debt
4,723
2,463
2,506
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.9%
-11.06%
12.92%
Free Cash Flow
24.39%
0.97%
-6.81%
Net Income, GAAP
-44.69%
-110.12%
-178.83%
Sales/Revenue/Turnover
12.46%
2.64%
-0.22%
Total Cash Common Dividend
8.2%
4.38%
3.74%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11,865
12,201
11,892
12,342
48,300
2025
11,201
12,269
12,222
12,503
48,195
2026
11,489
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-5.89
0.83
0.6
0.04
-4.41
2025
1.21
0.64
1.08
0.53
3.47
2026
1.31
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.6
0.6
0.6
0.6
2.4
2025
0.62
0.62
0.62
0.62
2.48
2026
0.63
- -
- -
- -
- -
Similar Companies
H. Lundbeck A/S (HLUN-A.CO)
Denis Chem Lab Limited (DENISCHEM.BO)
Shanxi Zhendong Pharmaceutical Co.,Ltd (300158.SZ)
Praveg Ltd. (PRAVEG.BO)
Royalty Pharma plc (RPRX)
Orphazyme A/S (0CUM.L)
Business
Bristol-Myers Squibb Company (NYSE: BMY; BMY.SW) is a global biopharmaceutical company that discovers, develops, and delivers innovative medicines for patients with serious diseases in oncology, hematology, immunology, cardiovascular, and neuroscience. The company, formed by the 1989 merger of Bristol-Myers (founded 1887) and Squibb (founded 1858), maintains headquarters in Princeton, New Jersey, with primary R&D sites in New Jersey, California, Massachusetts, Belgium, Japan, India, and the United Kingdom; it operates worldwide, generating 71% of 2024 revenues in the United States. Core products include Eliquis (apixaban; 28% of 2024 revenues) for stroke prevention in atrial fibrillation (co-marketed with Pfizer); Opdivo (nivolumab; 19%) for melanoma, lung cancer, and other solid tumors; Revlimid (lenalidomide; 12%) for multiple myeloma and myelodysplastic syndromes; Orencia (abatacept; 8%) for rheumatoid arthritis and other autoimmune diseases; Pomalyst/Imnovid (pomalidomide; 8%) for multiple myeloma and Kaposi sarcoma; Yervoy (ipilimumab; 5%) for cancer immunotherapy; Reblozyl (luspatercept; 4%) for anemia in beta thalassemia and myelodysplastic syndromes; CAR T therapies Abecma (idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel) for relapsed/refractory multiple myeloma and lymphomas; Camzyos (mavacamten) for obstructive hypertrophic cardiomyopathy; and Cobenfy (xanomeline/trospium) for schizophrenia. Recent developments encompass acquisitions of Karuna Therapeutics ($14 billion; March 2024) adding KarXT/Cobenfy for neuroscience; RayzeBio ($4.1 billion; February 2024) for actinium-based radiopharmaceuticals in oncology; Mirati Therapeutics ($4.8 billion plus $1 billion milestones; January 2024) bolstering precision oncology; Turning Point Therapeutics ($4.1 billion; 2022) for repotrectinib; and Orbital Therapeutics (2025) enhancing in vivo CAR T for autoimmune diseases; a $286 million buyout of partner 2seventy bio (2025) securing full Abecma rights; new partnerships including Bain Capital (July 2025) for immunology therapies, BioNTech (June 2025) for bispecific BNT327 in solid tumors, Cellares ($380 million; April 2024) for CAR T manufacturing, and SystImmune ($250 million milestone; 2025) for iza-bren ADC in breast cancer; and FDA approval of Cobenfy (September 2024) as the first novel schizophrenia treatment in 70 years.